What is the association between Tirzepatide (Moujaro) and visual disturbances?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 18, 2025 • View editorial policy

From the FDA Drug Label

5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. Inform patients to contact their healthcare provider if changes in vision are experienced during treatment with MOUNJARO [see Warnings and Precautions (5. 7].

Visual Issues with Moujaro:

  • Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
  • Inform patients to contact their healthcare provider if changes in vision are experienced during treatment with MOUNJARO. 1

From the Research

Mounjaro (tirzepatide) may cause visual issues in some patients, primarily due to its effect on rapid weight loss which can alter the fluid balance in the eye, as evidenced by its potent glucose lowering and weight loss effects 2. The most common visual side effects include blurred vision, changes in visual acuity, and in rare cases, diabetic retinopathy complications. If you experience any visual changes while taking Mounjaro, contact your healthcare provider immediately. These symptoms typically resolve on their own as your body adjusts to the medication, but they should never be ignored. Patients with pre-existing diabetic retinopathy should have a comprehensive eye exam before starting Mounjaro and regular follow-ups during treatment. The mechanism behind these visual changes relates to how GLP-1 receptor agonists like tirzepatide affect blood glucose levels and fluid balance throughout the body, including ocular tissues, as demonstrated in the SURPASS clinical trials 3. Rapid improvements in blood sugar control can temporarily worsen diabetic eye disease before eventually leading to improvement. Some key points to consider when taking Mounjaro include:

  • Starting with the recommended 2.5mg weekly dose before gradually increasing as directed by your healthcare provider
  • Staying hydrated to minimize side effects
  • Following your prescribed dosing schedule
  • Regular follow-ups with your healthcare provider to monitor for any potential visual issues. It is essential to prioritize the patient's overall health and well-being, considering the potential benefits of Mounjaro in improving glycemic control and weight loss, while also being aware of the potential risks and taking steps to mitigate them, as supported by the most recent and highest quality study available 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.